Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Chronic lymphocytic leukemia
Effectiveness
Ibrutinib
Real-world evidence
Safety
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
26
12
2023
accepted:
15
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
aheadofprint
Résumé
We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to the French marketing authorization in 2016 (i.e. patients with relapsed or refractory CLL or to previously untreated CLL patients with deletion 17p and/or tumor protein p53 mutations unsuitable for chemoimmunotherapy) and could have initiated ibrutinib more than 30 days prior their enrolment in the study (i.e. retrospective patients) or between 30 days before and 14 days after their enrolment (i.e. prospective patients). The results showed that in the effectiveness population (N = 388), the median progression-free survival (PFS) was 53.1 (95% CI: 44.5-60.5) months for retrospective patients and 52.9 (95% CI: 40.3-60.6) months for prospective patients and no difference was shown between the PFS of patients who had at least one dose reduction versus the PFS of patients without dose reduction (p = 0.7971 for retrospective and p = 0.3163 for prospective patients). For both retrospective and prospective patients, the median overall survival was not reached. The most frequent treatment-emergent adverse event of interest was infections (57.6% retrospective; 71.4% prospective). A total of 14.6% of the retrospective patients and 22.4% of the prospective patients had an adverse event leading to death. Our findings on effectiveness were consistent with other studies and the fact that patients with dose reductions had similar PFS than patients without dose reduction is reassuring. No additional safety concerns than those already mentioned in previous studies could be noticed.Trial registration ClinicalTrials.gov, NCT03425591. Registered 1 February 2018 - Retrospectively registered.
Identifiants
pubmed: 38443660
doi: 10.1007/s00277-024-05666-3
pii: 10.1007/s00277-024-05666-3
doi:
Banques de données
ClinicalTrials.gov
['NCT03425591']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Didier Adiko
(D)
Philippe Agape
(P)
Sophie Auger Quittet
(S)
Benoît Bareau
(B)
Omar Benbrahim
(O)
Philippe Bernard
(P)
Charles Bescond
(C)
Fontanet Bijou
(F)
Laurys Boudin
(L)
Sylvie Cailleres
(S)
Claire Calmettes
(C)
Guillaume Cartron
(G)
Régis Costello
(R)
Selva David
(S)
Jacques Delaunay
(J)
Caroline Delette
(C)
Sophie Dennetiere
(S)
Bernard Drenou
(B)
Abderrazak El Yamani
(A)
Alain Delmer
(A)
Olivier Fitoussi
(O)
Emmanuel Fleck
(E)
Joël Fleury
(J)
Jean Gutnecht
(J)
Maya Hacini
(M)
Éric Jourdan
(É)
Régis Kaphan
(R)
Jean-Michel Karsenti
(JM)
Jean-Luc Labourey
(JL)
Vincent Launay
(V)
Ronan Le Calloch
(R)
Isabelle Leduc
(I)
François Lefrere
(F)
Stevan Le Gall
(S)
Marielle Le Goff
(M)
Éric Legouffe
(É)
Steven Le Gouill
(S)
Stéphane Lepretre
(S)
Jixing Liu
(J)
Carine Luttiau Motard
(C)
Marius Moldovan
(M)
Lysiane Molina
(L)
Isabelle Moullet
(I)
Frédéric Peyrade
(F)
Philippe Quittet
(P)
Daniel Re
(D)
Virginie Roland
(V)
Damien Roos-Weil
(D)
Alain Saad
(A)
Hussam Saad
(H)
Delphine Senecal
(D)
Alexia Thannberger
(A)
Catherine Thieblemont
(C)
Olivier Tournilhac
(O)
Sorin Visanica
(S)
Informations de copyright
© 2024. The Author(s).
Références
Hallek M (2017) Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol 92:946–965
doi: 10.1002/ajh.24826
pubmed: 28782884
Ou Y, Long Y, Ji L et al (2022) Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study. Front Oncol 12:840616
doi: 10.3389/fonc.2022.840616
pubmed: 35359356
pmcid: 8961301
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Leukemia – Chronic Lymphocytic Leukemia (CLL). https://seer.cancer.gov/statfacts/html/clyl.html . Accessed 25 April 2023
Janssen-Cilag International NV (2014) IMBRUVICA [Summary of Product Characteristics]. Beerse, Belgium
European Medicines Agency. Imbruvica. https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica . Accessed 20 April 2023
Burger JA, Barr PM, Robak T et al (2020) Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34:787–798
doi: 10.1038/s41375-019-0602-x
pubmed: 31628428
Byrd JC, Brown JR, O’Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213–223
doi: 10.1056/NEJMoa1400376
pubmed: 24881631
pmcid: 4134521
Munir T, Brown JR, O’Brien S et al (2019) Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94:1353–1363
doi: 10.1002/ajh.25638
pubmed: 31512258
pmcid: 6899718
Woyach JA, Ruppert AS, Heerema NA et al (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379:2517–2528
doi: 10.1056/NEJMoa1812836
pubmed: 30501481
pmcid: 6325637
Chanan-Khan A, Cramer P, Demirkan F et al (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17:200–211
doi: 10.1016/S1470-2045(15)00465-9
pubmed: 26655421
Moreno C, Greil R, Demirkan F et al (2019) Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in frst-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:43–56
doi: 10.1016/S1470-2045(18)30788-5
pubmed: 30522969
Niemann C, Munir T, Moreno C et al (2022) Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): the glow study. Blood 140:228–230
doi: 10.1182/blood-2022-156070
Dartigeas C, Slama B, Doyle M et al (2022) FIRE study: real-world effectiveness and safety of ibrutinib in clinical practice in patients with CLL and MCL. Clin Hematol Int 4:65–74
doi: 10.1007/s44228-022-00015-5
pubmed: 36103041
pmcid: 9492818
Dartigeas C, Ysebaert L, Feugier P et al (2022) Overall and subgroup results from the third interim analysis of FIRE, a real-world study of ibrutinib treatment for CLL/SLL in France. Blood 140(S1):9906–9907
doi: 10.1182/blood-2022-155564
Byrd JC, Furman RR, Coutre SE et al (2015) Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125:2497–2506
doi: 10.1182/blood-2014-10-606038
pubmed: 25700432
pmcid: 4400288
European Medicines Agency. Adverse Event. https://www.ema.europa.eu/en/glossary/adverse-event#:~:text=An%20untoward%20medical%20occurrence%20after,necessarily%20caused%20by%20that%20medicine . Accessed 25 January 2024
Aarup K, Rotbain EC, Enggaard L et al (2020) Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. Eur J Haematol 105:646–654
doi: 10.1111/ejh.13499
pubmed: 32736410
O’Brien S, Furman RR, Coutre S et al (2018) Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131:1910–1919
doi: 10.1182/blood-2017-10-810044
pubmed: 29437592
pmcid: 5921964
UK Cll Forum (2016) Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica 101:1563–1572
doi: 10.3324/haematol.2016.147900
pmcid: 5479600
Brown JR, Hillmen P, O’Brien S et al (2014) Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood 124:3331–3331
doi: 10.1182/blood.V124.21.3331.3331
Winqvist M, Andersson P-O, Asklid A et al (2019) Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematologica 104:e208–e210
doi: 10.3324/haematol.2018.198820
pubmed: 30514799
pmcid: 6518914
Mato AR, Timlin C, Ujjani C et al (2018) Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. Br J Haematol 181:259–261
doi: 10.1111/bjh.14540
pubmed: 28220935
Hou J-Z, Ryan K, Du S et al (2021) Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Future Oncol 17:4959–4969
doi: 10.2217/fon-2021-0964
pubmed: 34783255
Hardy-Abeloos C, Pinotti R, Gabrilove J (2020) Ibrutinib dose modifications in the management of CLL. J Hematol Oncol 13:66
doi: 10.1186/s13045-020-00870-w
pubmed: 32503582
pmcid: 7275592
Niemann C, Munir T, Moreno C et al (2023) Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24:1423–1433
doi: 10.1016/S1470-2045(23)00452-7
pubmed: 37944541
Tam C, Allan JN, Siddiqi T et al (2022) Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139:3278–3289
doi: 10.1182/blood.2021014488
pubmed: 35196370